Enda Connolly - Healthy Diet for Healthy Life, Vienna, Feb 2014

1,193 views

Published on

Enda Connolly delivered a JPND presentation at the Healthy Diet for Healthy Life (HDHL) Management Board meeting in Vienna on February 20th, 2014

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

Enda Connolly - Healthy Diet for Healthy Life, Vienna, Feb 2014

  1. 1. JPND and HD4HL Enda Connolly JPND Management Board Member 20/02/2014
  2. 2. Joint Programming - a definition European countries engaging • voluntarily and on a variable geometry basis to tackle a major societal question • in the definition, development and implementation of a common strategic research agenda • based on a common vision on how to address major societal challenges.
  3. 3. We cannot tackle neurodegenerative diseases by acting as single countries JPND is a global research initiative led by EU countries, with 28 participating EU member states Associated countries Third countries Increasing coordination of national research programmes to improve impact and effectiveness Albania Austria Belgium Canada Croatia Czech Republic Denmark Finland France Germany Greece Hungary Ireland Israel Italy Luxembourg Netherlands Norway Poland Portugal Romania Slovakia Slovenia Spain Sweden Switzerland Turkey United Kingdom
  4. 4. JPND brings together…. • Researchers (Basic, Clinical, Healthcare/Social) • National Funding Bodies • National Research Strategies and Investments
  5. 5. Current JPND strategy To increase coordinated investment in ND research aimed at finding causes of disease, developing cures, and identifying appropriate ways to care for those with neurodegenerative diseases • Immediate JPND goals: • To add value to national investments through coordinated action • To encourage the development of national research strategies in ND • To engage in partnership to reach the full potential of JPND
  6. 6. Organisation Management Board • • • 27 countries represented Members mandated to act Chair Philippe Amouyel - France Executive Board • • • • Vice-Chair Adriana Maggi Robin Buckle Mogens Horder Marlies Dorlochter - Italy - UK - Denmark - Germany Steering Committee Executive Board + • Enda Connolly • Rainer Girgenrath • Edvard Beem - Ireland - Germany - Netherlands Scientific Advisory Board • 18 Members, chosen for scientific excellence and competence JPND currently partly supported by FP7-JUMPAHEAD (GA. 260774)
  7. 7. DEFRAGMENTATION - WHAT JPND IS ALL ABOUT STRATEGIC RESEARCH AGENDA ALIGNMENT OF EU COUNTRIES ON COMMON RESEARCH GOALS
  8. 8. Scope of the initiative Focus on Three Domains Scientific • Animal models • Biobanks • Cohorts/registries • Disease pathology Medical • Early diagnosis • Prevention • Clinical trials Social • Health care delivery • Home automation • Health economics • Ethics
  9. 9. JPND Research Strategy (SRA) • Agreed by 25 Member States + Assoc. Countries • • Officially Launched Feb 7th 2012 Thematic priorities for future research: • The origins of neurodegenerative disease • Disease mechanisms and models • Disease definitions and diagnosis • Developing therapies, preventive strategies and interventions • Healthcare and social care
  10. 10. JPND Research Strategy (SRA) • SRA Enabling Activities: • JPND will deliver the SRA within the next ten years through a combination of:          Knowing our research capability Opportunities for infrastructure and platforms Working in partnership with industry Working with the regulators Global partnership Capacity building Education and training Connection to policy makers Communication and outreach
  11. 11. How can JPND reach its goals? • Alignment of research in Member Countries • Partnership with the European Commission • Partnership with Industry • Partnership with other international organisations • Involvement of Patients and Public
  12. 12. JPND Actions to date • Common European Strategy • Phase I SRA Implementation (2012-2014) • Annual Transnational Calls for Proposals • Action Groups • National Plans and Strategies • Communication + Dissemination
  13. 13. SRA Implementation (2012-2014) Annual Calls for Proposals Year Total fund available Research Area No. of Projects 2011 €16M Optimization of biomarkers + harmonization of their use 4 2012 €18M Risk and Protective Factors 5 2012 €11M Evaluation of Healthcare 6 2013 €12M Cross-Disease Analysis Closed Feb 18th, 2014 2013 €11M Preventive Strategies Closed Feb 20th, 2014 (pilot) Centres of Excellence in Neurodegeneration (CoEN) 2011 €6M Phase I : common resources and methodological approaches 8 2012-13 €8M Phase II : “Pathfinder” projects 5
  14. 14. Call statistics No. of Budget No. of proposals requested proposals recommended (million €) supported for funding Year Call area of interest No. of proposals submitted 2011 Harmonization of Biomarkers 14 €31 5 4 €14 29% 2012 Risk and Protective Factors 52 €97 18 5 €17 10% 2012 Healthcare Evaluation 22 €29 9 6 €9 27% 88 €157m 32 15 €40m 17% Total Budget supported (million €) Success rate (%)
  15. 15. JPND-supported projects • Biomarker Harmonization • • Risk Factors • • • BIOMARKAPD: Standardizing biomarker measurements across Europe for Alzheimer’s and Parkinson’s Disease COURAGE-PD: Risk factor assessment for genetics and environment in Parkinson‘s Disease STRENGTH: Survival, Trigger and Risk, Epigenetic, Environmental and Genetic targets for Motor Neuron health Healthcare Evaluation • ALS-CaRE: A programme for ALS care in Europe • RHAPSODY: Research to access policies and strategies for dementia in the young
  16. 16. JPND-supported projects Fact Sheets Publications
  17. 17. SRA Implementation (2012-2014) Action Groups • To determine transnational research needs and opportunities • (chair: E. Connolly) • Animal and Cell Models (chair: A. Maggi) • Assisted Living Technologies (chair J. Hoogendam) • • Palliative Care Longitudinal Cohort Studies (chair: R. Buckle) To promote engagement, commitment and partnerships • Engagement and partnership with the EC (chair: P. Amouyel) • Engagement and Partnership with Industry (chair: A. Maggi) • User and Public Involvement in ND Research (chair: M. Horder) • Linkage + Alignment of National Plans and Initiatives (chair: E. Hirsch)
  18. 18. Action Group Recommendations
  19. 19. Partnership with the EC • Establish a programme of co-investment • Work towards a sustained increase of investments from JPND partners • Leverage the value of investments and resources at both national and EC level, to the benefit of Europe Examples: • Synergy between JPND actions and H2020 programme • Linking national plans through actions engaging national infrastructures • Development and long term sustainability of European cohorts • Unlocking national capability on fellowship programs
  20. 20. Partnership with the EC • • First call of Horizon 2020 (Dec. 2013) ERA-NET: • “Establishing synergies between the Joint Programming on Neurodegenerative Diseases Research and Horizon 2020”. • Proposal should: • coordinate national and regional programmes for research in the area of ND diseases research by implementing a transnational call with EU co-funding • Potential call topics: • Identification of genetic, epigenetic and environmental risk + protective factors • Longitudinal cohorts in ND research • Advanced experimental models of ND
  21. 21. Declaration from G8 summit on dementia • In response, the OECD is launching a project in 2014 for research on Alzheimer’s and dementia: • Aimed at strengthening international collaboration and promote data sharing at the international level • JPND invited to join the project Advisory Group • OECD plans a G8 mapping based upon JPND mapping methodology
  22. 22. Collaboration with JPI HDHL • Shared goals and activities • Possible collaboration
  23. 23. Trends of reduced dementia occurrence • At least five studies provide evidence suggesting that incidence of dementia may have decreased over the last 20 years (still, prevalence is increasing): • Rocca et al. Trends in the incidence and prevalence of Alzheimer’s disease, dementia, and cognitive impairment in the United States. Alzheimer’s & Dementia 2011 • Schrijvers et al. Is dementia incidence declining? Trends in dementia incidence since 1990 in the Rotterdam study. Neurology 2012 • Qiu et al. Twenty-year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden. Neurology 2013 • Christensen et al. Physical and cognitive functione of people older than 90 years: a comparison of two Danish cohorts born 10 years apart. The Lancet 2013 • Matthews et al. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II. The Lancet 2013 • Why? - Better awareness / treatment of lifestyle-related risk factors • Successful Prevention! Jan 28, 2014 Bengt Winblad, Karolinska Instituet, Sweden 23
  24. 24. Risk factors in AD; possible prevention ? Healthy brain Alzheimer brain What can we do ourselves to at least delay Alzheimer’s Disease onset? Some tested ”drugs” in prevention trials: Active lifestyle - Anti-inflammatory (eg NSAIDs) - Gingko Biloba - Vitamin B, C, D and E - Estrogens - ”Medical food” - Physical, Social, Mental Control of co-morbidity - Diabetes, Hypertension, Hypercholesterolemia - Souvenaid, Axona, Nestlé, Smartfish, Nutrition - ”Healthy” food intake Jan 28, 2014 Bengt Winblad, Karolinska Instituet, Sweden 24
  25. 25. Epidemiology/Risk factor research; Intervention – the way forward to 2025 Jan 28, 2014 Bengt Winblad, Karolinska Instituet, Sweden
  26. 26. Report of the Action Group on Longitudinal Cohort Studies ● JPND actions: for ND research on longitudinal cohort studies ● general population-based cohorts ● targeted (preclinical) and disease-focused cohorts ● 169 European studies examined ● Annexes provide detail on:  24 exemplar studies  33 studies on imaging measures  weblinks / references for all 169 cohorts ● Recommendations span ● co-ordination ● funding ● policy
  27. 27. Recommendations for delivery (Coordination) • Coordination and development of best practice • A series of JPND workshops to address challenges such as: • Preclinical stages of ND (methodologies, tools, measures e.g. • • • • • imaging) Cognition, behaviour & function: definitions of functional change, trajectory, outcomes Data handling: integration of -omics data, sharing big datasets Cohort alignment: where can data be pooled to provide benefit Clinical data linkage: how to exploit, harmonise, score, access Exploiting intervention studies of potential risk factors (vascular, T2D) to address ND risk as an outcome
  28. 28. Potential Next Steps • Arrange a small scientific working group • SAB-based? • Determine potential areas of collaboration • Identify possible actions • Report back to JPND and HD4HL
  29. 29. Keep up to date • Visit the JPND website: • http://www.neurodegenerationresearch.eu • http://www.jpnd.eu • Sign up to the JPND News Feeds • Follow JPND Progress pages • E-mail us: secretariat@jpnd.eu • Follow us on Twitter: @JPNDEurope

×